Merrimack Pharma (NASDAQ: MACK) announced updated clinical data from a multi-arm Phase 1 study of MM-141, a bispecific antibody targeting ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE